Nektar Therapeutics (NKTR) Leases: 2012-2025
Historic Leases for Nektar Therapeutics (NKTR) over the last 7 years, with Sep 2025 value amounting to $7.2 million.
- Nektar Therapeutics' Leases fell 18.75% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 18.75%. This contributed to the annual value of $8.4 million for FY2024, which is 53.28% down from last year.
- Per Nektar Therapeutics' latest filing, its Leases stood at $7.2 million for Q3 2025, which was down 5.46% from $7.6 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Leases ranged from a high of $125.0 million in Q1 2021 and a low of $7.2 million during Q3 2025.
- In the last 3 years, Nektar Therapeutics' Leases had a median value of $9.2 million in 2024 and averaged $15.9 million.
- Data for Nektar Therapeutics' Leases shows a maximum YoY tumbled of 71.55% (in 2023) over the last 5 years.
- Nektar Therapeutics' Leases (Quarterly) stood at $117.0 million in 2021, then tumbled by 54.34% to $53.4 million in 2022, then tumbled by 66.30% to $18.0 million in 2023, then tumbled by 53.28% to $8.4 million in 2024, then dropped by 18.75% to $7.2 million in 2025.
- Its last three reported values are $7.2 million in Q3 2025, $7.6 million for Q2 2025, and $8.0 million during Q1 2025.